Clinical Studies Of OvaRex In Advanced Ovarian Cancer Fail To Meet Primary Endpoint

United Therapeutics Corporation (Nasdaq: UTHR) and its wholly- owned subsidiary, Unither Pharmaceuticals, Inc., announced the completion of their two pivotal trials of OvaRex(R) MAb for the treatment of advanced ovarian cancer. Preliminary analysis demonstrates that the studies failed to reach statistical significance. [click link for full article]

More: continued here

Filed under: Cancer on December 6th, 2007